Wegovy in pill form: what it is and how it works

How does a tablet deliver semaglutide when injections have always been the standard?

Semaglutide is a large protein molecule. Swallowed alone, it would be broken down in the stomach before reaching the bloodstream, the reason injectable GLP-1 medicines became the norm. The Wegovy tablet solves this by combining semaglutide with SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate), a compound that temporarily raises the local pH around the tablet, allowing a meaningful amount of semaglutide to cross the stomach lining and enter circulation.

The practical implication is that how you take it matters considerably. The tablet must be swallowed first thing in the morning on an empty stomach, with no more than a small amount of plain water (up to around 120 ml). You then wait at least 30 minutes before eating, drinking anything else (including coffee or tea) or taking other oral medicines. Skip that window and absorption drops significantly. It is a different kind of routine from an injection, but many people find it fits naturally into a morning before the kettle has finished boiling.

One misconception worth clearing up gently: some people assume a tablet must be weaker or less clinically serious than an injection. The MHRA approval was based on a full phase 3 programme, held to the same regulatory standard as any other licensed medicine, and the dose at maintenance (25 mg) was selected specifically to overcome the absorption limitations of the oral route.

What does the dosing schedule for the pill form of Wegovy look like?

Treatment starts at 1.5 mg once daily. After roughly a month at that level, the prescriber moves the patient to 4 mg, then to 9 mg, and finally to the 25 mg maintenance dose, with at least one month spent at each rung before stepping up. Patients who are already established on the 2.4 mg weekly injection may move directly to the 25 mg tablet, but only under clinical review.

The schedule exists for the same reason the injection's titration exists: giving the digestive system time to adjust and keeping side effects manageable. The most common effects in the OASIS 4 trial were gastrointestinal, nausea, vomiting, and loose stools featured in around 74% of tablet users versus 42% of those on placebo, though most cases were mild to moderate and eased as the body settled. For context on how these effects compare across the injectable and oral versions, the full weight-loss profile of the Wegovy tablet covers what the evidence actually shows.

Because the tablet stores at room temperature, there is no cold chain to manage. No sharps bin, no pen device, no injection technique to learn. For some people that matters enormously; for others the once-weekly injection remains the more convenient option. A prescriber can help you work out which suits your life.

Who can currently access the pill form of wegovy through a private UK pharmacy?

The licensed eligibility criteria mirror those of the injection: adults with a BMI at or above 30, or a BMI of 27–29.9 alongside a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not determine suitability; a prescriber considers the full clinical picture, including any medicines you already take and relevant medical history.

The Wegovy pill is not yet available on the NHS, a NICE appraisal would be required before NHS commissioning could follow. That means access currently sits entirely within private prescribing. As with any prescription medicine, the only legal route is a clinical assessment followed by a prescription from a qualified prescriber. You can read about the private treatment options available at our consultation page, where a GPhC-registered prescriber personally reviews every application the same day it arrives.

Semaglutide tablets exist in another form worth naming: Rybelsus, at doses of 3 mg, 7 mg and 14 mg, is licensed for type 2 diabetes, not weight management. It is a different product with different licensed uses. If you have come across those dose numbers and are researching weight loss, the oral semaglutide explained page sets out the distinction clearly. The Wegovy weight-loss tablet schedule runs to 1.5 mg, 4 mg, 9 mg and 25 mg only.

What does the clinical evidence say about weight loss on the tablet?

The OASIS 4 trial (307 adults with obesity or overweight plus at least one weight-related condition, without diabetes, over 64 weeks) is the pivotal study behind the MHRA approval. Participants taking the tablet lost an average of around 13.6% of body weight, compared with roughly 2.4% on placebo, when all participants were included regardless of adherence. Among those who stayed fully on the treatment protocol throughout, the average reached approximately 16.6%. The MHRA approval announcement on 11 June 2026 sets out these figures, alongside the regulator's assessment of the benefit-risk profile.

For comparison, the 2.4 mg weekly injection produced around 15% average loss over 68 weeks in the STEP 1 trial, and the higher 7.2 mg injection dose has reported roughly 20.7% over 72 weeks. The tablet sits in a clinically meaningful range, particularly given that it removes injection as a barrier entirely. Whether the tablet or the injection is the better fit depends on individual factors, tolerability, lifestyle, and what a prescriber concludes after reviewing your health in full. The Wegovy tablet guide explores the practical side in more detail, and if you are still weighing up whether there is a pill form of Wegovy that suits your circumstances, our dedicated page covers the question in full alongside the semaglutide tablets overview, which places all oral forms in context.

Speak to our prescribers if you want a clinical view on whether the pill form of Wegovy suits your situation, consultations are free, and every review is carried out by a named, GPhC-registered Independent Prescriber on the day you apply.